This article was originally published in The Tan Sheet
Generics firm receives ANDA approval Sept. 23 for 100 mg/5 mL ibuprofen oral suspension, equivalent to McNeil's Children's Motrin. Perrigo and Alpharma recently settled FTC antitrust charges over a 1998 marketing agreement under which Perrigo marketed a Children's Motrin equivalent during Alpharma's exclusivity period (1"The Tan Sheet" Aug. 16, 2004, p. 3)...
You may also be interested in...
Perrigo is looking into developing its own line of private label statin drugs
The Federal Trade Commission's settlement with Perrigo and Alpharma suggests that deals struck between competing first-to-file generic drug manufacturers may trigger future antitrust scrutiny
A trial will begin next month in Mylan’s bid to overcome patents shielding AstraZeneca’s Symbicort respiratory brand in the US. With rival Teva having previously settled ANDA action, Mylan is in the driving seat for a first substitutable generic.